This a competitive renewal application for the Cancer Center Support Grant (CCSG) of Roswell Park Cancer Institute (RPCI) for the grant period 2000-2005. This grant is entering its 25th year of uninterrupted funding. Over the last three years RPCI has achieved tremendous new changes in its governance, increased Institutional Commitment to staff recruitment (38 new faculty within the next three years), major renovation of program facilities, expanded philanthropic funding, reorganization of clinical and scientific departments, established interactive scientific and clinical translational programs, strengthened its administrative infrastructure, and enhanced its programmatic relationship with the University at Buffalo. Under the leadership of Dr. David Hohn, President and CEO, RPCI is well-positioned to take advantage of new opportunities and challenges. The Center seeks a significant increase in CCSG funding to match its expanded Institutional commitment. The total request of $3,039,144 will support six scientific programs (Therapeutics, Biophysical Therapies, Immunology, Mouse Molecular Genetics, Cancer Genetics), two disease-oriented programs (Gastrointestinal Oncology, Breast Cancer Research), a Cancer Prevention and Control Program, fourteen shared resources and three clinical support units. The requested support has increased from approximately $1.5 million to $3.0 million. The increase is distributed as follows: New shared resources (25%), increased utilization of existing shared resources. (17%), expansion of shared resources (11%), developmental funds), and requests for salary of senior and program leadership (29%). The funds will be used to support 182 CCSG full members have peer-reviewed funding. With the new leadership, improved environment for basic and translational research, and an increased Institute financial commitment to program development, RPCI is poised to make significant new advances in prevention, early detection, diagnosis and treatment of cancer over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-26S1
Application #
6587774
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1983-12-01
Project End
2003-07-31
Budget Start
2002-05-01
Budget End
2003-07-31
Support Year
26
Fiscal Year
2002
Total Cost
$1,225,756
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19

Showing the most recent 10 out of 1555 publications